Antihypertensive Medication Management Before ARR Testing for Primary Aldosteronism
Use long-acting calcium channel blockers (either dihydropyridine or non-dihydropyridine) and/or alpha-1 receptor antagonists (doxazosin, prazosin, terazosin) as your primary antihypertensive regimen before measuring the aldosterone-renin ratio, as these agents do not interfere with test accuracy. 1
Two Acceptable Approaches to ARR Testing
The most recent 2024 ESC Guidelines 1 recognize that there are two valid strategies, though the "clean screen" approach is preferred when feasible:
Approach 1: Test Without Medication Changes (Pragmatic)
- Proceed with ARR testing on current medications to reduce barriers to screening
- Advantages: No risk of BP deterioration, faster screening, maintains patient safety
- Disadvantages: Results require specialist interpretation based on specific medications taken
- This approach is reasonable when stopping medications poses cardiovascular risk 1
Approach 2: Medication Optimization (Preferred for Accuracy)
This is the recommended approach when safe and feasible, as it provides the most reliable "clean" screening results.
Specific Medication Management Protocol
MUST WITHDRAW (4-6 weeks before testing):
- Mineralocorticoid receptor antagonists (spironolactone, eplerenone) - 4-6 weeks 2, 3
- Potassium-sparing diuretics (amiloride, triamterene) - 4 weeks 2, 4
- Potassium-wasting diuretics (thiazides, loop diuretics) - 2 weeks 2, 5
Exception: Recent evidence suggests MRAs may be continued if severe hypokalemia or severe hypertension makes withdrawal unsafe, particularly in florid primary aldosteronism 1
SHOULD WITHDRAW if BP control permits (2 weeks before testing):
- Beta-blockers - cause renin suppression leading to false positives 2, 1, 5
- ACE inhibitors and ARBs - stimulate renin, suppress aldosterone, causing false negatives 2, 6
- Centrally acting agents (clonidine, methyldopa) - suppress both renin and aldosterone 2, 1
- Dihydropyridine calcium channel blockers - 2 weeks 2
SAFE TO CONTINUE (Non-interfering agents):
- Long-acting verapamil or diltiazem (non-dihydropyridine CCBs) 2, 3, 4
- Long-acting dihydropyridine CCBs (per 2024 ESC) 1
- Alpha-1 receptor blockers (doxazosin, prazosin, terazosin) 2, 3
- Hydralazine 2, 3
Critical Pre-Test Conditions
Beyond medication management, ensure these conditions are met 2, 3, 4:
- Correct hypokalemia: Target serum potassium ≥4.0 mmol/L using potassium chloride (NOT potassium bicarbonate products)
- Liberal sodium intake: Minimum 5g/day sodium (>200 mmol/day) for 3 days
- Timing: Morning collection after patient ambulatory ≥2 hours
- Position: Seated 5-15 minutes before blood draw
- Avoid venous stasis during collection to prevent fictitious normokalemia
Important Caveats
Beta-blocker withdrawal paradox: The 2025 AHA/ACC Guidelines 6 note that while older guidance recommended withdrawal, growing evidence supports screening despite treatment with these medications. However, research shows beta-blockers cause a 62% increase in ARR and 100% false-positive rate in some studies 7, 8. My recommendation: withdraw beta-blockers when safe to do so.
ACE inhibitors/ARBs controversy: These drugs theoretically cause false negatives by raising renin. However, the 2017 ACC/AHA 3 notes that if renin remains undetectable despite these drugs, primary aldosteronism is strongly suspected. The 2024 research 9 suggests testing may proceed on these agents with appropriate interpretation.
Oral contraceptives: May cause false positives with direct renin concentration (not PRA). Discontinue 1 month before testing or use PRA instead 2
Practical Algorithm
Identify high-risk patients requiring screening (resistant hypertension, hypokalemia, adrenal incidentaloma, OSA with hypertension)
If BP well-controlled on non-interfering drugs: Proceed directly to testing
If on interfering medications:
- Switch to verapamil/diltiazem + doxazosin ± hydralazine
- Wait 2 weeks (4-6 weeks if on MRAs/K-sparing diuretics)
- Proceed to testing
If BP cannot be controlled without interfering drugs: Either test on current medications with specialist interpretation OR add centrally acting agents accepting slightly higher false-positive risk 1
Always correct hypokalemia and ensure adequate sodium intake before any testing approach
The 2024 ESC Guidelines 1 represent the most current thinking and explicitly acknowledge that the traditional strict medication withdrawal approach created barriers to screening, contributing to the dismally low 2-4% screening rates in eligible patients 1. The key is balancing diagnostic accuracy against patient safety and practical feasibility.